Abstract:
본 발명은 올리고 펩티드를 수식한 신규한 양이온성 지질, 그의 제조 방법 및 그를 포함하는 핵산 전달체를 제공한다. 본 발명의 양이온성 지질은 핵산 전달 체의 제조를 위해 사용된다. 본 발명의 양이온성 지질은 제조 및 정제 공정이 간편 하여 대량 생산시의 경제성이 높다. 또한, 본 발명의 양이온성 지질을 포함한 핵산 전달체는 세포 내로 전달하고자 하는 리보핵산, 작은 간섭 리보핵산, 안티센스 올 리고핵산, 핵산 앱타머(aptamer) 등의 올리고 핵산 의약을 세포 내로 수송하는 효 율을 현저히 증강시킬 뿐만 아니라, 세포 독성을 감소시켜 핵산 의약의 치료 효능 을 증강시키는 용도로 유용하게 사용된다.
Abstract:
본 발명은 키토산 또는 그 유도체가 지용성 비타민 또는 그 유도체와 결합된 양이온성 키토산 유도체, 그의 제조 방법 및 이를 포함하는 약물 전달체에 관한 것으로서, 본 발명의 양이온성 키토산 유도체는 세포 내로 전달하고자 하는 약제학적 유효성분을 세포 내로 수송하는 효율을 현저히 증강시킬 뿐만 아니라, 세포 독성을 감소시켜 약제학적 유효성분의 치료 효능을 증강시키는 용도로 유용하게 사용된다.
Abstract:
A cationic lipid is provided to ensure high profitability in mass production due to convenient manufacture and purification process, and to improve therapeutic efficacy of nucleic medicine by reducing cytotoxin. A cationic lipid has a structure represented by chemical formula (I). In chemical formula (I), n is an integer of 3-6; and R is C12-20 unsaturated hydrocarbon radical. An oligonucleic acid delivery system inside cells comprises the cationic lipid. The oligo nucleic acid is selected from the group consisting of ribonucleic acid, small interfering ribonucleic acid(siRNA), antisense oligonucleotide and nucleic acid aptamer. The delivery system formulation of the oligo nucleic acid is selected from the group consisting of liposomes, micelles, emulsions and nanoparticles.
Abstract:
A composition for delivering nucleic acids using a cationic polymer conjugate is provided to improve significantly the efficiency of delivering an oligo-nucleic acid such as siRNA and antisense nucleic acid in a cell and decrease the cytotoxicity caused by a carrier itself, thereby being usefully used in a field of targeting the delivery of the oligo-nucleic acid. A composition for delivering nucleic acids consists of 5-200 sequences of an animal cell including a cationic polymer conjugate formed by polymerizing hyaluronic acid and polyethylenimine using a crosslinking agent such as N-(2-dimethylaminopropyl)-N'-ethylcarbodiimide(EDC), 1-cyclohexyl-3-(2-morpholinoethyl) carbodiimide(CMC), dicyclohexyl carbodiimide(DCC), diisopropylcarbodiimide(DIC), N-ethyl-3-phenylisoxazolium-3'-sulfonate(Woodward's reagent K), and N,N'-carbonyldiimidazole(CDI). A composition for delivering nucleic acids in an animal cell includes a complex generated by an electrostatic bond between the cationic polymer conjugate with a nucleic acid.
Abstract:
PURPOSE: A cationic chitosan derivative which is bound with lipid-soluble vitamin or its derivative is provided to enhance the efficiency of transporting pharmaceutically effective ingredient into cells and improve treatment efficiency of the effective ingredient. CONSTITUTION: A cationic chitosan derivative has a structure of the chemical formula 1 or 2. The cationic chitosan derivative is prepared by reacting chitosan with lipid soluble vitamin using a coupling agent or protection group under the presence of a solvent. The protection group is phthalic anhydride. The reaction is performed under the presence of nucleophilic catalyst, DMAP[4-(Dimethylamino)pyridine]. A drug delivery system contains pharmaceutically effective ingredient and cationic chitosan derivative. The pharmaceutically effective ingredient is oligo nucleic acid. The drug delivery system has the form of liposome, micelle, emulsion, or nanoparticle.